Comparing the current results to its competitors, Instil Bio Inc reported Revenue decrease in the 2 quarter 2026 year on year by 0 %, despite the revenue increase by the most of its competitors of 11.15 %, recorded in the same quarter.
Instil Bio Inc 's Comment on Competition and Industry Peers
The company operates in the biotechnology and pharmaceutical industry, which is characterized by rapid technological change, intense competition, and a strong focus on intellectual property. It competes with major pharmaceutical, specialty pharmaceutical, and biotechnology companies, many of which have greater financial resources and expertise in acquisition, in-licensing, research and development, manufacturing, clinical trials, regulatory approvals, marketing, and recruiting qualified personnel. Competitors may develop and commercialize drugs that are safer, more effective, more convenient, or have fewer side effects, potentially limiting the company's commercial opportunities.
September 16, 2024
In a significant step forward in oncology, Instil Bio, Inc. (Nasdaq: TIL) and ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (HKEX:1541) have unveiled an ambitious global registrational strategy for their innovative PD-L1xVEGF bispecific antibody, SYN-2510/IMM2510. This development is particularly noteworthy as the drug is being positioned as a front-line treatment for two of the most challenging cancers: non-small cell lung cancer (NSCLC) and triple-negative breast cancer (TNBC). Announced on September 16, 2024, the partnership marks a pivotal moment in the ongoing battle against these aggressive malignancies. Understanding the Challenge of NSCLC and TNBCNon-small cell lung cancer and triple-negative breast ...
August 1, 2024
In an industry-defining collaboration, Instil Bio, Inc. (Nasdaq: TIL, Instil) and ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (HKEX Code: 1541.HK, ImmuneOnco) have announced a landmark agreement focusing on innovative immunotherapy solutions. The pivotal development saw Instil obtaining exclusive ex-China development and commercial rights to ImmuneOnco’s pioneering PD-L1xVEGF bispecific antibody, IMM2510, along with a next-generation anti-CTLA-4 antibody, IMM27M.This collaboration positions both companies at the forefront of immunotherapy advancements, targeting complex mechanisms in the tumor microenvironment to bolster anti-cancer efficacy. The focus on PD-L1xVEGF and anti-CTLA-4 antibodies aims to exp...
Avalon Globocare Corp's business model is focused on providing innovative healthcare solutions and services through strategic acquisitions, partnerships, and collaborations in the biotechnology and healthcare sectors.
Dyadic International Inc's business model revolves around developing and licensing proprietary microbial strains and technologies for use in the biopharmaceutical, biofuels, and industrial enzyme industries.
Estrella Immunopharma Inc is a biotechnology company that focuses on developing innovative immunotherapies. They have a business model centered around researching, developing, and commercializing novel treatments for various diseases. Their approach includes leveraging the power of the immune system to target and eradicate diseases, with a particular emphasis on cancer.
Immunitybio Inc operates on a business model that focuses on developing and commercializing innovative immunotherapies and vaccines to address various diseases and medical conditions. They aim to use their broad scientific expertise, technology platforms, and strategic partnerships to advance their products and improve patient outcomes in healthcare.
Intensity Therapeutics Inc's business model involves developing and commercializing novel intratumoral cancer immunotherapy products. They aim to target and destroy tumors within the body through the direct application of their proprietary drug, leading to an enhanced immune response and potential treatment for various cancers.
Sources:
Instil Bio Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Instil Bio Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
